Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.39 |
| ▸ | F2 | P00734 | 4/20 | 0.39 |
| ▸ | F7 | P08709 | 2/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 3/20 | 0.37 |
| ▸ | PLG | P00747 | 2/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268953 | 0.93 | HCAR3 (0.40) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL6498866 | 0.88 | HCAR3 (0.33) | SCN10A | |
| SCHEMBL6264978 | 0.81 | F10 (0.40) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL6500557 | 0.81 | HCAR3 (0.38) | SCN10A | |
| SCHEMBL6243588 | 0.78 | SCN10A (0.37) | SCN10A | |
| SCHEMBL12545642 | 0.74 | KDM4E (0.50) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL3830602 | 0.74 | F10 (0.47) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL6243680 | 0.74 | APEX1 (0.37) | F10F2F7PRSS1PLAU | |
| SCHEMBL3834356 | 0.73 | F10 (0.46) | F10F2F7TPSAB1PRSS1 | |
| SCHEMBL6244968 | 0.72 | SCN10A (0.35) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919331-B2 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207868-A1 | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | F10 4670/4885F2 4176/4885F7 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.